Gabapentin Capsule
Product Images NDC 68071-2366

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2366). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2366 1)

Gabapentin 300 mg capsules label from NuCare Pharmaceuticals, Inc. The label states the product contains 100 capsules and is prescription-only (Rx only). It includes the NDC 68071-2366-1 and manufacturer details. Additional storage and safety warnings are visible, along with barcodes and lot/serial numbers.*

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over an 8-week period comparing Gabapentin 3600 mg/day and placebo. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating that pain scores declined more significantly with Gabapentin than with placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis shows time in weeks from baseline through a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis represents the mean pain score from 0 to 10. Gabapentin treatment groups show a decrease in pain scores compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' showing comparison between placebo (PBO) and gabapentin (GBP) at various dosages (3600 mg, 1800 mg, 2400 mg) across two studies. The y-axis indicates proportion values from 0% to 100%, with gabapentin groups having notably higher responder percentages than placebo, with statistically significant differences denoted by asterisks.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

The image displays a mathematical formula for calculating creatinine clearance (CLCr). The formula includes variables for age, weight, and serum creatinine, with an adjustment factor for female patients. It is a text-based representation relevant to pharmacokinetic calculations.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure diagram of gabapentin, showing its molecular framework with a cyclohexane ring and attached amino and carboxylic acid groups, consistent with the active ingredient gabapentin.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing the percentage difference on the y-axis and daily dosage in mg on the x-axis for Gabapentin. It compares results from three studies labeled a, b, and c at daily doses of 600, 900, 1200, and 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.